ACAD Gets FDA Nod, High-Five For ABBV's Imbruvica, NLNK Waits To Impress

ACADIA Pharmaceuticals Inc.'s (ACAD) NUPLAZID has been approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID, which becomes the first and only medicine to be approved by the FDA for this indication, is expected to be launched in the U.S. next month.

from RTT - Biotech http://ift.tt/21oXSjS
via IFTTT